Checkpoint inhibition reduces the threshold for drug-specific T-cell priming and increases the incidence of sulfasalazine hypersensitivity
S Hammond, A Olsson-Brown, S Grice… - Toxicological …, 2022 - academic.oup.com
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
[PDF][PDF] Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
S Hammond, A Olsson-Brown, S Grice… - TOXICOLOGICAL …, 2022 - apconix.com
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
[PDF][PDF] Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
S Hammond, A Olsson-Brown, S Grice… - TOXICOLOGICAL …, 2022 - pure-oai.bham.ac.uk
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity.
S Hammond, A Olsson-Brown, S Grice… - Toxicological …, 2022 - search.ebscohost.com
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
[HTML][HTML] Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
S Hammond, A Olsson-Brown, S Grice… - Toxicological …, 2022 - ncbi.nlm.nih.gov
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
[PDF][PDF] Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
S Hammond, A Olsson-Brown, S Grice… - TOXICOLOGICAL …, 2022 - core.ac.uk
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
[PDF][PDF] Checkpoint inhibition reduces the threshold for Drug-Specific T-Cell priming and increases the incidence of sulfasalazine hypersensitivity
S Hammond, A Olsson-Brown… - …, 2022 - researchportal.murdoch.edu.au
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
S Hammond, A Olsson-Brown… - … : an official journal …, 2022 - pubmed.ncbi.nlm.nih.gov
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
[PDF][PDF] Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
S Hammond, A Olsson-Brown, S Grice… - Toxicological …, 2022 - academic.oup.com
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
[PDF][PDF] Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
S Hammond, A Olsson-Brown… - TOXICOLOGICAL …, 2022 - research.birmingham.ac.uk
An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …
on the tolerability of concomitant medications. One report of this phenomenon was the …
